'A missed opportunity': The biggest takeaways from the FDA's underwhelming gene therapy hearing
Researchers and executives hoping that the FDA’s two-day hearing on gene therapy would offer a clear direction for the field’s future came away disappointed.
For 16 hours, the agency listened to presentations and debated everything from AAV-driven cancers in mice to how concerned we should be about strange MRI results in patients given direct injections in the brain. But few firm conclusions or recommendations ever arrived.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.